期刊文献+

去中心化临床试验设计和实施要点探析

Analysis on the key points in the design and implementation of decentralized clinical trials
原文传递
导出
摘要 去中心化临床试验(decentralized clinical trial,DCT)作为以患者为中心临床试验可供选择的模式之一,可以加快临床试验进程、改善受试者体验、提高临床试验数据质量。尽管如此,与大多数创新一样,DCT也增加了临床试验过程的复杂性,给临床试验带来额外风险。本文从DCT的特点与优势、应用的场景、设计实施需要考虑的因素、DCT元素引入、风险及应对措施进行探讨,以期为DCT的实践提供思路。 Decentralized Clinical Trials(DCT),as one of the clinical trial modes that can be selected in patient⁃centered clinical trials,can significantly shorten the time course of entering market for new drugs or devices,improve the experience of clinical trial participants and enhance the quality of clinical data.However,DCT,like most new innovations,will increase the complexity of the clinical trial process and may also bring in unknown risks.This article explores the features and advantages,the feasibility of application,the factors to consider in design and implementation,elements,risk and countermeasure of DCT,in order to provide references and ideas for the practice of DCT.
作者 肖爽 李高扬 董瑞华 朱雪琦 王晶 曹彩 程金莲 XIAO Shuang;LI Gao-yang;DONG Rui-hua;ZHU Xue-qi;WANG Jing;CAO Cai;CHENG Jin-lian(Beijing Hospital of Traditional Chinese Medicine,Capital Medical University,Beijing 100010,China;Lingyan Innovation(Beijing)Health Technology Co.,Ltd.,Beijing 101121,China;Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China;Zhongguancun Jiutai Good Clinical Practice Union,Beijing 100027,China)
出处 《中国新药杂志》 CAS CSCD 北大核心 2024年第17期1773-1777,共5页 Chinese Journal of New Drugs
基金 国家“重大新药创制”科技重大专项资助项目(2019ZX09734001)。
关键词 去中心化临床试验 应用 设计 实施 decentralized clinical trial application design implementation
  • 相关文献

参考文献3

二级参考文献16

  • 1全国人民代表大会常务委员会.《中华人民共和国药品管理法》[S].2015.
  • 2Clinical Outcome Assessment ( COA). Glossary of Terms [ EB/ OL]. [ 2015 -04 -30 ]. http://www, fda. gov/drugs/develop- mentapprovalprocess/drugdevelopmenttoolsqualificationprogram/ ucm370262, htm.
  • 3ICH Guideline:Statistical Principles for Clinical Trials[ EB/OL]. [ 2015 - 11 -03 ]. http ://www. ich. org/fileadmin/Public_Web_ Site/ICH _ Products/Guidelines/Efficacy/E9/Step4/E9 _ Guide- line. pdf.
  • 4WHO. International Classification of Functioning, Disability and Health[ S]. 2001.
  • 5亚瑟·J阿特金森,达雷尔·R.阿伯内西,查尔斯·E.丹尼尔斯,等著.魏伟译.临床药理学原理[M].第2版.北京:科学出版社社,2008:229-230.
  • 6国家食品药品监督管理总局.中药新药临床研究一般原则[S].2015.
  • 7C ode Federal egultation, title21, Part314.51 O, H [ S ]. 1999.
  • 8FDA. Draft Guidance for Industry, Tool Developers, and Food and Drug Administration Staff [ S]. 2013.
  • 9FDA. Guidance for Industry Patient-Reported Outcome Meas- ures: Use in Medical Product Development to Support Labeling Claims[ S]. 2009.
  • 10肖德才,符湘云,胡荍,熊晓红,余元华,来瑞平,谢多双.基于SAS的住院量灰色预测及实现[J].中国卫生统计,2012,29(4):586-587. 被引量:11

共引文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部